Hormone Therapy and Risk of Breast Cancer: Where Are We Now?

Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Micha, John P., Rettenmaier, Mark A., Bohart, Randy D., Goldstein, Bram H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Menopause 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452594/
https://www.ncbi.nlm.nih.gov/pubmed/36070869
http://dx.doi.org/10.6118/jmm.21035
_version_ 1784784944610934784
author Micha, John P.
Rettenmaier, Mark A.
Bohart, Randy D.
Goldstein, Bram H.
author_facet Micha, John P.
Rettenmaier, Mark A.
Bohart, Randy D.
Goldstein, Bram H.
author_sort Micha, John P.
collection PubMed
description Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. Hence, physicians and nurses should actively engage in constructive discourse with their patients regarding HRT while specifically reviewing the potential risks of its extended use as well as provide the available medical alternatives the patients could potentially use.
format Online
Article
Text
id pubmed-9452594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Menopause
record_format MEDLINE/PubMed
spelling pubmed-94525942022-09-14 Hormone Therapy and Risk of Breast Cancer: Where Are We Now? Micha, John P. Rettenmaier, Mark A. Bohart, Randy D. Goldstein, Bram H. J Menopausal Med Review Article Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. Hence, physicians and nurses should actively engage in constructive discourse with their patients regarding HRT while specifically reviewing the potential risks of its extended use as well as provide the available medical alternatives the patients could potentially use. The Korean Society of Menopause 2022-08 2022-08-31 /pmc/articles/PMC9452594/ /pubmed/36070869 http://dx.doi.org/10.6118/jmm.21035 Text en Copyright © by The Korean Society of Menopause https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ).
spellingShingle Review Article
Micha, John P.
Rettenmaier, Mark A.
Bohart, Randy D.
Goldstein, Bram H.
Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
title Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
title_full Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
title_fullStr Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
title_full_unstemmed Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
title_short Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
title_sort hormone therapy and risk of breast cancer: where are we now?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452594/
https://www.ncbi.nlm.nih.gov/pubmed/36070869
http://dx.doi.org/10.6118/jmm.21035
work_keys_str_mv AT michajohnp hormonetherapyandriskofbreastcancerwherearewenow
AT rettenmaiermarka hormonetherapyandriskofbreastcancerwherearewenow
AT bohartrandyd hormonetherapyandriskofbreastcancerwherearewenow
AT goldsteinbramh hormonetherapyandriskofbreastcancerwherearewenow

Ejemplares similares